CAS 104862-31-9

Fórmula: C21H20N4O5S

InChI: InChI=1S/C21H20N4O5S/c1-21(23-24-22)13-31(28,29)17-12-16(26)25(17)19(21)20(27)30-18(14-8-4-2-5-9-14)15-10-6-3-7-11-15/h2-11,17-19H,12-13H2,1H3/t17-,19+,21-/m1/s1

Chave InChI: PHVJTTUXSHSWDV-SLYNCCJLSA-N

SMILES: C[C@]1(CS(=O)(=O)[C@@H]2CC(=O)N2[C@H]1C(=O)OC(C3=CC=CC=C3)C4=CC=CC=C4)N=[N+]=[N-]

Tazobactam Acid Impurity 35

CAS: 104862-31-9

Fórmula: C₂₁H₂₀N₄O₅S

Peso molecular: 440.47

Ref: 4Z-T-127044

Tazobactam Acid Impurity 35

CAS: 104862-31-9

Fórmula: C₂₁H₂₀N₄O₅S

Peso molecular: 440.47

Ref: ST-EA-CP-T129019

[2R-(2Alpha,3Beta,6Alpha)]-3-Azido-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]octane-2-carboxylic Acid 5,5-Dioxide Diphenylmethyl Ester

Produto Controlado

CAS: 104862-31-9

Applications [2R-(2α,3β,6α)]-3-Azido-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]octane-2-carboxylic Acid 5,5-Dioxide Diphenylmethyl Ester is an intermediate in the synthesis of Tazobactam Sodium Salt-13C2,15N1 (T010102), which is a labelled analogue of Tazobactam Sodium Salt (T010100), which is a β-Lactamase inhibitor, used with β-lactam antibiotics to enhance their effect.
References Gould, I.M., et al.: Drugs Exp. Clin. Res., 17, 187 (1991); Roland, R.K., et al.: J. Infect. Dis., 4, 226 (2000), Bonomo, R.A., et al.: Biochim. Biophys. Acta, 1547, 196 (2001);

Fórmula: C₂₁H₂₀N₄O₅S

Cor e Forma: Neat

Peso molecular: 440.47

Ref: TR-A926600